Known as the bodys "metabolic master switch," AMPK activation mimics the physiological effects of high-intensity exercise
Studies have demonstrated that GLP-1 medications have the potential to lead to significant weight loss in individuals with obesity or overweight
Originally developed to treat type-2 diabetes, some GLP-1 drugs have been approved for weight management in the past three years
EGCG and its metabolites have been identified in biological fluids such as serum, plasma, saliva, feces, and urine, as well as in various organs and tissues, including the liver, kidneys, intestinal mucosa (small intestine and colon), prostate, tumor tissues, fetuses, and placenta
doi:10.1016/0016-5085(89)90081-4
bylelikle vcut hcreleri korumas da salanm olur